The Tell-tale heart: Population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction

PLoS ONE

Volumn 2, Issue 9, 2007, Pages

  Borwnstein, John S ^a,b,c   Sordo, Margarita ^a,d   Kohane, Isaac C ^a,c,d,e   Mandi, Kenneth D ^a,b,c,e  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Harvard Medical School Center for Biomedical Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; LACTONE; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HEART INFARCTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRESCRIPTION; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; UNITED STATES; CHEMICALLY INDUCED DISORDER; HEALTH SURVEY;

CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 41049092271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000840     Document Type: Article

References (52)

1. Mortality from coronary heart disease and acute myocardial infarction-United States, 1998. MMWR Moth Mortal Wkly Rep 50: 90-93.
2. American Heart Association (2005) Heart Disease and Stroke Statistics-2005 Update. Dallas, Texas.
3. Willich SN, Lewis M, Lowel H, Arntz HR, Schubert F, et al. (1993) Physical exertion as a trigger of acute myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study Group. N Engl J Med 329: 1684-1690.
4. Rosenberg L, Palmer JR, Shapiro S (1990) Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 322: 213-217.
5. Hu FB, Stampfer MJ, Marison JE, Rimm E, Colditz GA, et al. (1997) Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 337: 1491-1499.
6. Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, et al. (2007) Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J.
7. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, et al. (1998) A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339: 719-724.
8. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM (2001) Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 96: 1698-1703.
9. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Bmj 332: 1302-1308.
10. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 24 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475-481.
11. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Bmj 330: 1366.
12. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068-2073.
13. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99: 132-140.
14. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
15. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091.
16. Mukherjec D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 286: 954-959.
17. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
18. Rawson NS, Malcolm E (1995) Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 14: 2627-2643.
19. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, et al. (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148: 99-104.
20. Hutwagner LC, Maloney EK, Bean NH, Slutsker L, Martin SM (1997) Using laboratory-based surveillance data for prevention: an algorithm for detecting Salmonella outbreaks. Emerg Infect Dis 3: 395-400.
21. Davis RL. Kolezak M, Lewis E, Nordin J, Goodman M, et al. (2005) Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology 16: 336-341.
22. Hauben M, Zhou X (2003) Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 26: 159-186.
23. Williams SM, Parry BR, Schlup MM (1992) Quality control: an application of the cusum. Bmj 304: 1359-1361.
24. McCullagh P, Nelder JA (1989) Generalized Linear Models. London: Chapman and Hall.
25. IMS Health (2006) Commonly Requested Therapeutic Class and Product Information. In: Health I, editor IMS Health.
26. Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, et al. (2006) Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 113: 2285-2292.
27. Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenasc-2 inhibitors: a population study of elderly adults. Ann Intern Med 142: 481-489.
28. Mandl KD, Overhage JM, Wagner MM, Lober WB, Sebastiani P, et al. (2004) Implementing syndromic surveillance: a practical guide informed by the early experience. J Am. Med Inform Assoc 11: 141-150 [PrePrint published Nov 121, 2003; as doi:2010.1197./jamia.M1356].
29. Reis BY, Pagano M, Mandl KD (2003) Using temporal context to improve biosurveillance. Proc Natl Acad Sci U S A 100: 1961-1965.
30. Tsui FC, Espino JU, Dato VM, Gesteland PH, Hutman J, et al. (2003) Technical description of RODS: a real-time public health surveillance system. J Am Med Inform Assoc 10: 399-409.
31. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 1522 p following 1528.
32. Curfman GD, Morrissey S, Drazen JM (2005) Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,"' N Engl J Med 2000;343:1520-8. N Engl J Med 353: 2813-2814.
33. Milane MS, Suchard MA, Wong ML, Licinio J (2006) Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States. PLoS Med 3: e190.
34. Baune B, Hay P (2066) Suicide rates and antidepressant prescribing: a casual or causal relationship? PLoS Med 3: e220.
35. Psaty BM, Furberg CD (2005) COX-2 inhibitors-lessons in drag safety. N Engl J Med 352: 1133-1135.
36. Topol EJ (2004) Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 351: 1707-1709.
37. Waxman HA (2005) The lessons of Vioxx-drug safety and sales. N Engl J Med 352: 2576-2578.
38. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
39. Psaty BM, Furberg CD (2097) Rosiglitazone and cardiovascular risk. N Engl J Med 356: 2522-2524.
40. Avorn J (2006) Evaluating drug effects in the post-Vioxx. world: there must be a better way. Circulation 113: 2173-2176.
41. Drazen JM (2005) COX-2, inhibitors-a lesson in unexpected problems. N Engl J Med 352: 1131-1132.
42. IOM (2006) The Future of Drug Safety: Promoting and Protecting the Health of the Public.
43. Ray WA, Stein CM (2006) Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 354: 194-201.
44. Crawford LM (2005) Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference. Food Drug Law J 60: 99-102.
45. Food and Drug Administration (2003) MedWatch Reporting by Consumers.
46. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358: 1872-1873.
47. Mann RD (2004) Assessments of disproportionality. Pharmacoepidemiol Drug Saf 13: 501-502.
48. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Lagnaoui et al. (2003) Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindol. Pharmacoepidemiol Drug Saf 12:271-281.
49. Strom BL (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. Jama 292: 2643-2646.
50. Psaty BM, Furberg CD, Pay WA, Weiss NS (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. Jama 292: 2622-2631.
51. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, et al. (2004) A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001.
52. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. Jama 296: 2947-2953.